ATXS Valuation

Astria Therapeutics Inc

Add to Watchlist

Advanced Chart

6.850

+0.09(1.331%)1D

Overview
Forecast
Valuation
Earnings

ATXS Relative Valuation

ATXS's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, ATXS is overvalued; if below, it's undervalued.

Historical Valuation

Astria Therapeutics Inc (ATXS) is now in the Fair zone, suggesting that its current forward PS ratio of 24.68 is considered Fairly compared with the five-year average of -3.88. The fair price of Astria Therapeutics Inc (ATXS) is between to according to relative valuation methord.

Relative Value

Fair Zone

Current Price：6.85

Fair

-3.25

Trailing

Forward

-1.34

EV/EBITDA

Astria Therapeutics Inc. (ATXS) has a current EV/EBITDA of -1.34. The 5-year average EV/EBITDA is -1.67. The thresholds are as follows: Strongly Undervalued below -4.88, Undervalued between -4.88 and -3.27, Fairly Valued between -0.06 and -3.27, Overvalued between -0.06 and 1.55, and Strongly Overvalued above 1.55. The current Forward EV/EBITDA of -1.34 falls within the Historic Trend Line -Fairly Valued range.

-1.73

EV/EBIT

Astria Therapeutics Inc. (ATXS) has a current EV/EBIT of -1.73. The 5-year average EV/EBIT is -2.03. The thresholds are as follows: Strongly Undervalued below -5.41, Undervalued between -5.41 and -3.72, Fairly Valued between -0.33 and -3.72, Overvalued between -0.33 and 1.36, and Strongly Overvalued above 1.36. The current Forward EV/EBIT of -1.73 falls within the Historic Trend Line -Fairly Valued range.

24.68

Astria Therapeutics Inc. (ATXS) has a current PS of 24.68. The 5-year average PS is 0.18. The thresholds are as follows: Strongly Undervalued below -4.05, Undervalued between -4.05 and -1.94, Fairly Valued between 2.29 and -1.94, Overvalued between 2.29 and 4.41, and Strongly Overvalued above 4.41. The current Forward PS of 24.68 falls within the Strongly Overvalued range.

-3.82

P/OCF

Astria Therapeutics Inc. (ATXS) has a current P/OCF of -3.82. The 5-year average P/OCF is -2.80. The thresholds are as follows: Strongly Undervalued below -9.41, Undervalued between -9.41 and -6.10, Fairly Valued between 0.51 and -6.10, Overvalued between 0.51 and 3.82, and Strongly Overvalued above 3.82. The current Forward P/OCF of -3.82 falls within the Historic Trend Line -Fairly Valued range.

-2.88

P/FCF

Astria Therapeutics Inc. (ATXS) has a current P/FCF of -2.88. The 5-year average P/FCF is -2.19. The thresholds are as follows: Strongly Undervalued below -8.52, Undervalued between -8.52 and -5.35, Fairly Valued between 0.98 and -5.35, Overvalued between 0.98 and 4.15, and Strongly Overvalued above 4.15. The current Forward P/FCF of -2.88 falls within the Historic Trend Line -Fairly Valued range.

Astria Therapeutics Inc (ATXS) has a current Price-to-Book (P/B) ratio of 2.34. Compared to its 3-year average P/B ratio of 4.40 , the current P/B ratio is approximately -46.85% higher. Relative to its 5-year average P/B ratio of 4.00, the current P/B ratio is about -41.47% higher. Astria Therapeutics Inc (ATXS) has a Forward Free Cash Flow (FCF) yield of approximately -30.01%. Compared to its 3-year average FCF yield of -19.54%, the current FCF yield is approximately 53.56% lower. Relative to its 5-year average FCF yield of -32.07% , the current FCF yield is about -6.43% lower.

2.34

P/B

Median3y

4.40

Median5y

4.00

-30.01

FCF Yield

Median3y

-19.54

Median5y

-32.07

Competitors Valuation Multiple

The average P/S ratio for ATXS's competitors is 6.06, providing a benchmark for relative valuation. Astria Therapeutics Inc Corp (ATXS) exhibits a P/S ratio of 24.68, which is 307.17% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

ATXS.O

Astria Therapeutics Inc

Y-mAbs Therapeutics Inc

Olema Pharmaceuticals Inc

Loss

378.18M

FULC.O

Fulcrum Therapeutics Inc

Loss

-100.00%

368.90M

Performance Decomposition

Market capitalization of ATXS increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of ATXS in the past 1 year is driven by Unknown.